A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2022-05-27
Adverse events
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-06-14 (study day 9); relationship: N
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-10-09 (study day 126); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-12 (study day 129); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-09-16 (study day 468); relationship: N
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-21 (study day 595); relationship: not assessed
Grade 3 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-02-07 (study day 612); relationship: not assessed; serious criteria: hospitalization
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2024-03-21 (study day 655); relationship: not assessed
Data queries
No data queries.